{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:07:28Z","timestamp":1755907648525,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bulcan.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:50:22Z","timestamp":1751421022000},"page":"714-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formes familiales de cancer du sein\u00a0\u2013\u00a0d\u00e9pistage g\u00e9n\u00e9tique et surveillance en fonction du risque"],"prefix":"10.1016","volume":"112","author":[{"given":"Jessica","family":"Moretta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorine","family":"Livon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Nogu\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12\u201313","key":"10.1016\/j.bulcan.2025.04.005_bib0005","first-page":"188","article-title":"Incidence des principaux cancers en France m\u00e9tropolitaine en 2023\u00a0et tendances depuis 1990","author":"Lap\u00f4tre-Ledoux","year":"2023","journal-title":"Bull Epidemiol Hebd"},{"year":"2019","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Volume 1. Tumeurs solides","author":"Defossez","key":"10.1016\/j.bulcan.2025.04.005_bib0010"},{"journal-title":"Synthese","article-title":"D\u00e9pistage du cancer du sein en France\u202f: identification des femmes \u00e0 haut risque et modalit\u00e9s de d\u00e9pistage","year":"2014","key":"10.1016\/j.bulcan.2025.04.005_bib0015"},{"year":"2022","series-title":"\u00a9 Oncog\u00e9n\u00e9tique en 2020\/consultations & laboratoires, suivi en 2019 et 2020, collection Appui \u00e0 la d\u00e9cision","key":"10.1016\/j.bulcan.2025.04.005_bib0020"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.005_bib0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.005_bib0030","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk Tool\u00a0\u2013\u00a0a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0035","unstructured":"Place de l\u2019oncos\u00e9nologue dans la prescription des analyses oncog\u00e9n\u00e9tiques La Lettre du S\u00e9nologue no\u00a090\u00a0\u2013\u00a0d\u00e9cembre 2020"},{"issue":"25","key":"10.1016\/j.bulcan.2025.04.005_bib0040","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1 \u2013\u00a0or BRCA2\u00a0\u2013 mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2025.04.005_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2025.04.005_bib0050","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0055","unstructured":"L\u00e9gifrance\u00a0\u2013\u00a0Loi no\u00a02004-800\u00a0du 6\u00a0ao\u00fbt 2004\u00a0relative \u00e0 la bio\u00e9thique https:\/\/www.legifrance.gouv.fr\/affichTexte.do?."},{"year":"2019","series-title":"\u00a9Inhibiteurs de PARP\u00a0: pr\u00e9conisations pour un parcours en g\u00e9n\u00e9tique oncologique, collection Outils pour la pratique","author":"INCa","key":"10.1016\/j.bulcan.2025.04.005_bib0060"},{"issue":"10","key":"10.1016\/j.bulcan.2025.04.005_bib0065","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bulcan.2018.08.003","article-title":"Recommandations fran\u00e7aises du Groupe g\u00e9n\u00e9tique et cancer pour l\u2019analyse en panel de g\u00e8nes dans les pr\u00e9dispositions h\u00e9r\u00e9ditaires au cancer du sein ou de l\u2019ovaire","volume":"105","author":"Moretta","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0070","unstructured":"L\u00e9gifrance\u00a0\u2013\u00a0D\u00e9cret no\u00a02013-527\u00a0du 20\u00a0juin 2013\u00a0relatif aux conditions de mise en oeuvre de l\u2019information de la parent\u00e8le dans le cadre d\u2019un examen des caract\u00e9ristiques g\u00e9n\u00e9tiques \u00e0 finalit\u00e9 m\u00e9dicale https:\/\/www.legifrance. gouv.fr\/affichTexte.do? cidTexte=JORFTEXT000027592003."},{"issue":"5182","key":"10.1016\/j.bulcan.2025.04.005_bib0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"6559","key":"10.1016\/j.bulcan.2025.04.005_bib0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.bulcan.2025.04.005_bib0085","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1\u00a0and BRCA2\u00a0mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bulcan.2025.04.005_bib0090","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes\u00a0\u2013\u00a0association analysis in more than 113,000\u00a0women","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2025.04.005_bib0095","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2\u00a0pathogenic variants: an international study of 524\u00a0families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.005_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary diffuse gastric cancer syndrome: CDH1\u00a0mutations and beyond","volume":"1","author":"Hansford","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.005_bib0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.005_bib0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jmedgenet-2012-101339","article-title":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome","volume":"50","author":"Bubien","year":"2013","journal-title":"J Med Genet"},{"issue":"10","key":"10.1016\/j.bulcan.2025.04.005_bib0115","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"23","key":"10.1016\/j.bulcan.2025.04.005_bib0120","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53\u00a0mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0125","unstructured":"Plan France M\u00e9decine G\u00e9nomique 2025. https:\/\/pfmg2025.aviesan.fr\/."},{"year":"2017","key":"10.1016\/j.bulcan.2025.04.005_bib0130"},{"issue":"8","key":"10.1016\/j.bulcan.2025.04.005_bib0135","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.bulcan.2025.04.005_bib0140","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/jmg-2024-109943","article-title":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2\u00a0pathogenic variant carriers","volume":"61","author":"Yang","year":"2024","journal-title":"J Med Genet"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0145","first-page":"130","article-title":"Haut risque de cancer du sein\u00a0: une RCP d\u2019\u00e9valuation et de recommandations","volume":"2","author":"Moretta","year":"2016","journal-title":"Innov Ther Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.04.005_bib0150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10549-021-06333-1","article-title":"Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311\u00a0women","volume":"189","author":"Evans","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.bulcan.2025.04.005_bib0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","article-title":"Society of surgical oncology breast disease Working Group Statement on prophylactic (risk-reducing) mastectomy","volume":"24","author":"Hunt","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.04.005_bib0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1016\/j.bulcan.2025.04.005_bib0165","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41436-020-0862-x","article-title":"Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1\u00a0and BRCA2\u00a0pathogenic variants","volume":"22","author":"Barnes","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2022.11.007","article-title":"Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease","volume":"179","author":"Jiao","year":"2023","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2025.04.005_bib0175","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1\u00a0or BRCA2\u00a0mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.005_bib0180","first-page":"585","article-title":"Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants","volume":"7","author":"Choi","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.005_bib0185","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/cancers15041141","article-title":"Prophylactic radical fimbriectomy with delayed oophorectomy in women with a high risk of developing an ovarian carcinoma: results of a prospective national pilot study","volume":"15","author":"Leblanc","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bulcan.2025.04.005_bib0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10689-016-9910-8","article-title":"An investigation of the factors effecting high-risk individuals\u2019 decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC)","volume":"15","author":"Hallowell","year":"2016","journal-title":"Fam Cancer"},{"key":"10.1016\/j.bulcan.2025.04.005_bib0195","unstructured":"L\u00e9gifrance\u00a0\u2013\u00a0D\u00e9cret no\u00a02016-1185\u00a0du 30\u00a0ao\u00fbt 2016\u00a0relatif \u00e0 la participation des assur\u00e9s pour les frais li\u00e9s au d\u00e9pistage sp\u00e9cifique du cancer du sein en cas de risque \u00e9lev\u00e9 https:\/\/www.legifrance.gouv.fr\/eli\/decret\/2016\/8\/30\/AFSS1613779D\/jo\/texte."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T13:22:05Z","timestamp":1755868925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125002590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":39,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0007455125002590"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.04.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formes familiales de cancer du sein\u00a0\u2013\u00a0d\u00e9pistage g\u00e9n\u00e9tique et surveillance en fonction du risque","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}